Trial Profile
A Phase III Study to Evaluate the Efficacy and Safety of Xolair (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2020
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Feb 2020 Status changed from recruiting to completed.
- 10 Jun 2019 Planned End Date changed from 16 Sep 2019 to 18 Sep 2019.
- 10 Jun 2019 Planned primary completion date changed from 16 Sep 2019 to 18 Sep 2019.